BergenBio Fundamentale Forhold (BGBIO)

[Matadoren]

Fordi de kan ikke slippe resultatene før den varslede presentasjonen starter, men samtidig slik at det foreligger lik informasjon.

[HeldigFyr]

Etter flere selskaper som måtte avslutte sine covid treatment forsøk begynte jeg å tville om Bemcentinib skulle oppnå signifikant statistisk forskjell. Spennende å følge med i tiden som kommer.

[Poyken]

Da er det muligens tiden hvor de tålmodige også blir enda mer optimistiske. Det er et godt utgangspunkt for veien videre tatt i betraktning de andre go-meldinger i den senere tid.

[TekBot]

BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY

Bergen, Norway, 21 July 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that pre-clinical data
…

Vis børsmeldingen

evaluating bemcentinib, BerGenBio’s first-in-class, potent and highly selective
AXL inhibitor, for the treatment of SARS-CoV-2 infection has been presented at
the 40[th] Annual American Society for Virology (ASV).

The presentation was given by BerGenBio’s collaborator, Mr. Dana Bohan, a PhD
candidate from the University of Iowa, who outlined previously announced
findings from preclinical studies conducted in the Lab of Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa. The studies
aimed to evaluate AXL as a therapeutic target for COVID-19 infection and the
potential effect of BerGenBio’s selective AXL inhibitor bemcentinib to prevent
infection by SARS-CoV-2. The investigators concluded that phosphatidylserine
receptors, such as AXL, enhance SARS-CoV-2 infection and that inhibition of AXL
is a potentially promising therapeutic target for COVID-19.

New data investigating bemcentinib against SARS-CoV-2 mutations was also
presented. These data show that bemcentinib is also efficacious in preventing
SARS-CoV-2 infection by carrying circulating mutations. Details on the
presentation can be found below.

Presenter: Mr. Dana Bohan, PhD candidate, University of Iowa

Title: Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a
Therapeutic Target for COVID-19

Workshop: W16: Receptors, Attachment and Entry

Presentation Time: July 20, 2021 at 2:45 PM to 3:00 PM Eastern Time

The presentation will be made available at BerGenBio’s website,
www.bergenbio.com.

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated in infected organs with an
activation of the signalling pathway leading to suppression of the Type 1
Interferon immune response by infected cells and neighbouring cells, in their
environment. Pre-clinical research studies demonstrate that bemcentinib inhibits
SARS-CoV-2 host cell entry and promotes anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine -based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[LosFidro]

Ikke for å være streng eller sur, men fint om slike kommentarer holdes til småpratkanalen. Blir så rask mye støy på fundamentaltråden med slike småkommentarer

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @anon28800809 (671 likes)

@anon28800809

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia | BMC Cancer | Full Text (publisert 17. juni 2021)

2. @vcp (255 likes)

@vcp

3. @Hayen (153 likes)

@Hayen

vcp,

Resten av topp 10:

4. @Direkte (147 likes)

5. @Scrivener (110 likes)

6. @Roc (82 likes)

7. @Matadoren (55 likes)

8. @Mykle (46 likes)

9. @alfred_e_neuman (40 likes)

10. @CanonBoy (32 likes)

Gratulerer!

[TekBot]

BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS

Bergen, Norway, 4 August 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, will be announcing its results for the second quarter
…

Vis børsmeldingen

and half year 2021 on Tuesday 17 August 2021. A webcast presentation by
BerGenBio’s senior management team will take place at 10:00 am CET.

The live webcast link will be available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

The second quarter report and presentation will be available on the Company’s
website in the Investors/Financial Reports section from 7:00 am CET the same
day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Kilde

[TekBot]

BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT

Bergen, Norway, 6 August 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces changes to its clinical development
…

Vis børsmeldingen

team structure in preparation for late-stage clinical trials of lead candidate
bemcentinib and increased activity in medical and scientific regulatory affairs.

Prof. Hani Gabra has transitioned from Chief Medical Officer to a part-time
position as Director of Clinical Development, to focus on the scientific
elements of clinical trial design and the important parallel translational
research being undertaken by BerGenBio. Dr E. Gwyn Thomas has joined the Company
as interim Head of Clinical Development.

Dr E. Gwyn Thomas is a physician specializing in medical oncology and clinical
pharmacology and has over 25 years of experience in pharmaceutical medicine,
drug development and medical affairs. Dr Thomas has held senior leadership roles
at Wyeth Research, Genzyme Europe, Ibsen, Blue Earth Diagnostics and Mundipharma
Research. During his career, Dr Thomas has successfully managed several New Drug
Applications in the US, Japan and Singapore, as well as Marketing Authorisation
Applications across Europe.

Richard Godfrey, Chief Executive Officer of BerGenBio commented “We are pleased
to welcome Gwyn to BerGenBio. This is an exciting time for the Company as we
continue to advance our lead candidate bemcentinib. With strong data obtained so
far, Gwyn’s extensive experience will be crucial as we continue our dialogue
with both EU and US regulators on the potential initiation of pivotal
registration trials for this promising candidate.”

• END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated in infected organs with an
activation of the signalling pathway leading to suppression of the Type 1
Interferon immune response by infected cells and neighbouring cells, in their
environment. Pre-clinical research studies demonstrate that bemcentinib inhibits
SARS-CoV-2 host cell entry and promotes anti-viral Type I interferon response.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[vcp]

For en melding!
Dette har jeg ventet på.
Prof. Hani Gabra er en stjerne.

Nå nærmer vi oss begynnelsen av en rekke skudd på mål. Her som i fotball er det rutine og erfaring som gjelder.

[vcp]

Merittene er ikke noe å si på, men siste tids prestasjoner er ikke spesielt imponerende.
Sammenligningen med Tippeligaen er for beskjeden, vi er nok i La liga / Serie A.

Flere Fast track av FDA blandt dem i verdens styggeste kreft indikasjon. Samt en potensiell fot innenfor verdens værste pandemi i nyere tid. Veldig god PR.

[alfred_e_neuman]

Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor–Mediated AXL Phosphorylation

Published: August 02, 2021
https://www.kidneymedicinejournal.org/article/S2590-0595(21)00167-9/fulltext (DOI)

IgA nephropathy (IgAN) is a common glomerular disease, with mesangial-cell proliferation as a major feature. There is no disease-specific treatment. Platelet-derived growth factor (PDGF) contributes to the pathogenesis of IgAN. To better understand its pathogenic mechanisms, we assessed PDGF-mediated AXL phosphorylation in human mesangial cells and kidney-tissue biopsy specimens.

Immunoprecipitation experiments indicated association of AXL and PDGF-receptor (PDGFR) proteins. An AXL-specific inhibitor (bemcentinib) partially blocked PDGF-induced cellular proliferation and reduced phosphorylation of AXL and PDGFR and the downstream signals (AKT1, ERK1/2).

PDGF-mediated signaling in mesangial cells involves transactivation of AXL. Finding appropriate inhibitors to block PDGF-mediated transactivation of AXL may provide new therapeutic options for mesangioproliferative kidney diseases, such as IgAN.

(Bemcentinib, also known as BGB324 or R428)

[tverilytt]

Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Emerging therapies such as omab-B CD45 and Actimab-A CD33, Ficlatuzumab, Devimistat, BST236, Bemcentinib, Pracinostat, are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.

https://www.getnews.info/1153352/acute-myeloid-leukemia-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments.html#ixzz73GAM3zTE

[TekBot]

BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021

Bergen, Norway, 17 August 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces its results for the second quarter and
…

Vis børsmeldingen

first half of 2021.

A presentation and live webcast by BerGenBio’s senior management will take place
at 10.00 am CEST today, please see below for details.

Operational Highlights - second quarter of 2021 (including post-period end)

COVID-19

Update from Phase II trials assessing bemcentinib in hospitalised COVID-19
patients (April)

· Data from BGBC020 and ACCORD2 showed bemcentinib was well tolerated by
patients with no safety concerns
· In both studies there was a numerically lower number of deaths in
the bemcentinib arm vs. standard of care (1 vs 5 and 2 vs 3 respectively)

Pre-clinical COVID-19 data presented at Virtual Immunology Conference 2021 (May)

· Data from a preclinical COVID-19 study conducted by Professor Wendy Maury
showed that SARS-CoV-2 utilizes TIM1 and AXL as key pathways for virus entry and
that inhibition of AXL signalling by BerGenBio’s selective
inhibitor bemcentinib reduces infection

Top line data from Phase II (BGBC020) trial assessing bemcentinib in
hospitalised COVID-19 patients (May)

· Post-hoc analysis identified more than 50% of patients with the most severe
disease showed evidence of treatment effect by bemcentinib, although the primary
endpoint did not achieve statistical significance
· Data from BGBC020 trial showed that bemcentinib has the potential to
increase the rate of ventilator free survival to 90% compared to 72% with SOC on
its own in more than 50% of COVID-19 patients
· Overall, in the combined studies, survival to day 29 was 96.5% (83 of 86
evaluable patients) in bemcentinib arm versus 91.0% (81 of 89) treated with SOC
alone
· Bemcentinib anti-viral mechanism of action supported by analysis
· Bemcentinib was well tolerated throughout

Encouraging combined bemcentinib data from Phase II COVID-19 studies presented
at ECCMID (July)

· Data from BGBC020 and ACCORD2 showed increased survival of 96.6% in
bemcentinib arm vs. 91.2% in standard of care arm
· Significantly reduced likelihood (69%) of progression to ventilation in
higher severity cohort
· Significantly increased likelihood (88%) of shorter time to recovery or
discharge in higher severity cohort
· Clinical evidence of anti-viral mechanism of action
· Preclinical analysis highlights bemcentinib’s potential against COVID-19
variants

COVID-19 data presented at The Annual American Society For Virology (July)

· Presentation given by BerGenBio’s collaborator, Mr. Dana Bohan, a PhD
candidate from the University of Iowa, who outlined previously announced
findings from preclinical studies conducted in the Lab of Professor Wendy Maury
· New data investigating bemcentinib against SARS-CoV-2 mutations showed that
bemcentinib is also efficacious in preventing SARS-CoV-2 infection by carrying
circulating mutations

Non-Small Cell Lung Cancer

FDA fast track designation received for bemcentinib / anti-PD-(L)1 combination
in NSCLC (June)

· Fast track designation received for the treatment of patients with AXL
-positive advanced/metastatic non-small cell lung cancer (NSCLC)
· First recognition by a regulator of AXL-positive patients as a target
population

Acute Myeloid Leukaemia

Encouraging updated preliminary data from Phase II relapsed AML study presented
at EHA (June)

· Preliminary survival data with bemcentinib more than doubles historic
survival data with standard of care
· Durable responses were observed in the relapsed AML setting, with an overall
response rate of 36% (4/11) and median overall survival not achieved at data cut
off, but 12 month survival at 70%.

Tilvestamab

Preclinical bemcentinib and tilvestamab data presented at European Association
of Urology 2021 (July)

· Preclinical data from study investigating bemcentinib and tilvestamab in
renal cell carcinoma (RCC) showed that both drugs prevented Gas-6-induced AXL
phosphorylation in vitro and effectively prevented tumour growth in an
orthotopic RCC xenograft model in vivo

Financial Highlights - second quarter of 2021

(Figures in brackets = same period 2020 unless otherwise stated)

· Revenue amounted to NOK 0.0 million (NOK 0.0 million)
· Total operating expenses for Q2 were NOK 92.3 million (NOK 64.7 million),
and for the first half NOK 175.7 million (NOK 121.0 million)
· Operating loss for Q2 of NOK 92.3 million (NOK 64.7 million), and for
the first half NOK 175.7 million (NOK 121.0 million), reflecting the level
of activity related to the clinical trials BerGenBio is conducting
· Cash and cash equivalents decreased to NOK 574.0 million by 30 June 2021
(NOK 659.4 by 31 March 2021 and NOK 828.4 by 30 June 2020)

Richard Godfrey, Chief Executive Officer of BerGenBio, commented:

"The second quarter of 2021 has seen BerGenBio continue to make progress across
its oncology programs, with significant updates from our ongoing trial in Acute
Myeloid Leukaemia (AML). Given the strong data obtained so far, we have
continued our dialogue with EU and US regulators on the potential initiation of
a pivotal registration trial for the combination of bemcentinib and LDAC in
relapsed elderly AML patients unfit for intensive chemotherapy.

"In addition to our lead programmes in oncology, we remain hopeful that
bemcentinib could be an effective treatment for COVID-19. The need for effective
therapeutic interventions against COVID-19 remains high and is driven by the
continuous threat of new, potentially vaccine resistant strains of the virus.

“With ongoing interaction with regulators, Government and industry partners,
with positive clinical data, and a clear business strategy in place, we are
looking forward to the year ahead.”

Presentation and Webcast Details

A presentation by BerGenBio’s senior management team will take place today at
10:00 am CET and be webcast live.

Webcast link: https://channel.royalcast.com/landingpage/hegnarmedia/20210817_3/

Dial-in numbers:

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

PIN: 712491

The Q2 and HY 2021 Financial report and presentation are available on the
Company’s website in the Investors/Financial Reports section and a recording of
the webcast will be made available shortly after the webcast has finished.

-Ends-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive and therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad Phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia, and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify those patient populations most
likely to benefit from bemcentinib or tilvestamab: this is expected to
facilitate more efficient registration trials and support a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO).

For further information, please visit: www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Media Relations

Mary-Jane Elliot, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO ASA: LEDERSKIFTE

Bergen, Norge, 22. august 2021?- BerGenBio ASA (OSE:BGBIO), et biofarmasøytisk
selskap i klinisk fase som utvikler nye, selektive AXL-hemmere for krefttyper
med behov for forbedret behandlingstilbud, kunngjør utnevnelsen av Martin Olin
…

Vis børsmeldingen

som ny administrerende direktør fra 8. september 2021.

Etter 12 år som administrerende direktør i BerGenBio, har Richard Godfrey
besluttet å tre av som administrerende direktør i selskapet med umiddelbar
virkning for å forfølge andre forretingsinteresser. Rune Skeie, finansdirektør i
BerGenBio, tiltrer rollen som midlertidig administrerende direktør frem til 8.
september 2021.

Martin Olin bringer mer enn 20 års ledererfaring innen farmasøytisk og
bioteknologisk industri til BerGenBio. Han var tidligere administrerende
direktør i Symphogen, et bioteknologiselskap med fokus på utvikling av
proteinmedisiner basert på rekombinante monoklonale antistoffbehandlinger, kjøpt
opp av Servier i 2020.

Før han startet i Symphogen i 2012, var Olin senior partner hos SLS Invest, et
skandinavisk helsefokusert private equity-fond. Han har tidligere hatt
lederstillinger i Novo Nordisk inklusive finansdirektør for EMEA. Senest har han
fungert som Managing Partner for Nordic Eye, et København-basert Venture Capital
-selskap.

Sveinung Holde, styreleder i BerGenBio kommenterte: "Martin har lang erfaring
som leder innen biovitenskap med gode resultater. BerGenBio har nådd en kritisk
fase, med sin hovedkandidat bemcentinib som viser lovende data og fremgang i
lungekreft, leukemi og potensielt COVID-19. Styret er enig om at Martin er
ideelt kvalifisert til å lede BerGenBio inn i den neste fasen av utviklingen.

Jeg vil takke Richard personlig og på vegne av hele BerGenBio for hans dedikerte
arbeid de siste tolv årene. Richard har spilt en avgjørende rolle i etableringen
av BerGenBio som et selskap i klinisk fase og har ledet selskapet gjennom den
globale COVID-19 pandemien. Vi ønsker ham lykke til i fremtiden."

Martin Olin, administrerende direktør i BerGenBio, kommenterte: “BerGenBio har
vært banebrytende for forståelsen av AXL-biologi og potensialet for AXL-hemming
som en hjørnestein i terapi for alvorlige sykdommer. Jeg ser spent frem til å
bli en del av selskapet og til å samarbeide med styret og teamet for å fortsette
utviklingen av vår hovedkandidat bemcentinib, og selskapets øvrige pipeline av
legemiddelkandidater, gjennom videre klinisk utvikling og til slutt til
pasientene som vi tror vil ha nytte av dem.”

Richard Godfrey, kommenterte: “Jeg har hatt stor glede av å lede BerGenBio de
siste 12 årene og vil følge spent med på fremdriften med bemcentinib etter hvert
som den utvikler seg gjennom de neste spennende fasene. Det er nå en naturlig
tid for meg å overlate roret til Martin. Jeg ønsker styret og hele firmaet lykke
til i fremtiden.”

-Slutt-

Selskapets kontakter

Sveinung Hole, styreleder, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, interim administrerende direktør og finansdirektør, BerGenBio ASA
rune.skeie@bergenbio.com

Internasjonal mediakontakt

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Om BerGenBio ASA

BerGenBio er et kliniskfase biofarmasøytisk selskap som setter søkelys på å
utvikle transformative medisiner rettet mot AXL som en potensiell hjørnestein i
terapi for aggressive sykdommer, inkludert immununnvikende og
medikamentresistente kreftformer. Selskapets proprietære hovedkandidat,
bemcentinib, er en potensiell første-i-klasse selektiv AXL-hemmer i et bredt
fase-II onkologisk klinisk utviklingsprogram med fokus på kombinasjons- og
enkeltmiddelterapi i lungekreft, leukemi og COVID-19. En første-i-klasse
funksjonsblokkerende anti-AXL-antistoff gjennomgår klinisk fase I-tester.
Parallelt utvikler BerGenBio en «companion diagnostic» test for å identifisere
de pasientpopulasjonene som mest sannsynlig vil dra nytte av AXL-hemming: dette
forventes å legge til rette for mer effektive registreringsforsøk som støtter en
presisjonsmedisinbasert kommersialiseringsstrategi.

BerGenBio har base i Bergen, Norge med et datterselskap i Oxford, Storbritannia.
Selskapet er notert på Oslo Børs (ticker: BGBIO). For mer informasjon, besøk
www.bergenbio.com

Denne informasjonen er vurdert å være innside informasjon etter EU
markedsmisbruk forordning og er informasjonspliktig etter verdipapirhandelloven
§ 5-12.

Kilde

[E24Bot]

Toppsjefen går på dagen i Bergenbio

Toppsjefen går på dagen i Bergenbio

[TekBot]

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 23 August 2021

The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company’s share capital by NOK 27,000 by issuance
of 270,000 new shares. The new shares are subscribed for by option owners who
wishes and are entitled to exercise options in accordance with the Company’s
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme, in average NOK 10.86 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,823,275.50 consisting of 88,232,755 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Rune Skeie

Interim CEO and CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Share capital increase

Bergen, Norway, 26 August 2021 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 August 2021 where
the Company announced that the board of directors of the Company had resolved to
…

Vis børsmeldingen

increase the Company’s share capital in connection with the exercise of options
pursuant to the Company’s share option program. A total of 270,000 options were
exercised and 270,000 new shares were issued at an average subscription price of
NOK 10.86 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,823,275.50 divided into 88,232,755 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Rune Skeie

Interim CEO and CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are
not historical facts, but are based upon various assumptions, many of which
are based, in turn, upon further assumptions. These assumptions are
inherently subject to significant known and unknown risks, uncertainties and
other important factors. Such risks, uncertainties, contingencies and other
important factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[ESHoyem]

Noen som kan, i korte trekk forklare hva evt utfall er?

[Matadoren]

Mest sannsynlig så er det avgåtte CEO som har innløst sine opsjoner, sist gang lånte han aksjer og solgte samme dag som varselet om innløsning ble publisert (dvs da slipper han kontant utlegg), og det er jo noen dager siden nå. Så enten har han allerede solgt noe eller alt, eller så har han aksjene klare for salg til en passende anledning . Tror neppe du vil se den posten bli lagt ut på best i åpnings
auksjonen

[ESHoyem]

Hjertelig. Synes bare prisinga var så rar, men kan svært lite om det og. Antar dette da ikke vil påvirke kursen på noen måte?